The Intelligent Prevention And Control System And Strategy For The Whole Disease Cycle Of Diabetic Nephropathy

Launched by CHINESE PLA GENERAL HOSPITAL · Feb 20, 2025

Keywords

ClinConnect Summary

This clinical trial is focused on finding better ways to prevent and manage diabetic nephropathy, a serious kidney problem that can occur in people with type 2 diabetes (T2DM). The goal is to create a comprehensive system that tracks the entire progression of diabetic nephropathy, which is important because it can lead to severe health issues, including kidney failure. Researchers will collect data from large groups of people to identify risk factors and develop new technologies for monitoring kidney health. They will also use artificial intelligence to analyze this information and create models that can help predict which patients are at greater risk for kidney problems.

To participate in this study, individuals need to be at least 18 years old and have been diagnosed with type 2 diabetes for more than five years but must show no signs of kidney damage. Healthy individuals aged 40 to 80 can also join, as well as patients who have diabetes and have undergone a kidney biopsy. Participants can expect regular follow-ups and assessments to help improve the understanding and treatment of diabetic nephropathy. Overall, this trial aims to enhance patient care and reduce the risk of serious kidney disease in the future.

Gender

ALL

Eligibility criteria

• • T2DM
• Inclusion Criteria:
• • Age ≥18 years old, gender is not limited
• • Diagnosed with type 2 diabetes
• • A history of type 2 diabetes for more than 5 years
• • Negative proteinuria
• • Creatinine is normal
• • Good compliance, voluntarily sign informed consent
• Exclusion Criteria:
• • Incomplete medical records
• • Lack of fundus microvascular examination or new imaging technology examination results data
• • Combined with autoimmune diseases and tumors
• • Type 2 diabetes patients undergoing renal biopsy
• Inclusion Criteria:
• • Age ≥18 years old, gender is not limited
• • Diagnosed with type 2 diabetes
• • Kidney damage (microalbuminuria or dominant albuminuria or renal insufficiency)
• • Have undergone renal puncture biopsy and have complete renal pathological diagnosis data
• • Sign informed consent voluntarily
• Exclusion Criteria:
• • Gestational diabetes mellitus, special type diabetes mellitus
• • Patients with hereditary kidney disease
• • Combined with autoimmune diseases
• • Diabetic nephropathy The indicators in the comprehensive assessment model of the risk of renal progression could not be obtained
• • There were pregnancy plans in the study period